Sameera Tallapureddy, MD
Endocrinology, Diabetes & Metabolism · Allen, TXNPI 1669642799
Payments from drug & device makers
Across 1,126 payments — averaging $124.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$83K
- Dexcom, Inc.$29K
- Eli Lilly$11K
- Ascensia Diabetes Care US Inc.$3K
- Mannkind Corporation$1K
- Amgen$1K
- plus $11K from 54 others
What the payments were for
- Consulting fees$10,3757%
- Speaking & faculty fees$95,92968%
- Travel & lodging$13,90410%
- Food & beverage$19,72314%
- Education$1240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$72,794
- DEXCOM G7 GSS (161)$28,191
- DEXCOM STELO GLUCOSE BIOSENSOR$15,404
- Kerendia$244
- EVENITY$146
- MINIMED 770G$138
- t:slim X2 Insulin Pump with Control-IQ$124
- Veozah$123
- TEPEZZA$112
- INPEN SMART INSULIN DELIVERY SYSTEM$111
- V-GO$110
- FARXIGA$108
- AFREZZA$107
- Prolia$103
How this compares
$140,055 in reported general payments places this provider in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 163 | $277,421 |
| MounjaroTirzepatide | 170 | $192,461 |
| JardianceEmpagliflozin | 61 | $76,484 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 47 | $65,548 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 49 | $54,484 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $52,997 |
| TrulicityDulaglutide | 37 | $47,373 |
| Tresiba Flextouch U-100Insulin Degludec | 59 | $47,270 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $34,359 |
| FarxigaDapagliflozin Propanediol | 28 | $32,244 |
| RybelsusSemaglutide | 13 | $20,104 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 26 | $16,488 |
| Gvoke Hypopen 2-PackGlucagon | 13 | $10,267 |
| HumalogInsulin Lispro | 24 | $10,134 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $10,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,264 | $305,629190 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $82,904 | $249,968231 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $470 | $142,032108 claims |
| AstraZenecaFarxiga | $1,155 | $32,24428 claims |
| AbbVieSynthroid | $412 | $6,16057 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $228 | $3,722159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Allen
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
- Thomas BlevinsAustin$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.